Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
1,325 total articles
Cineverse Corp. (NASDAQ: CNVS) Chief People Officer Mark Torres purchased 25,000 shares of Class A Common Stock on February 17, 2026, at $2.00 per share, a transaction totaling $50,000. The purchase boosts Torres' direct stake to 183,274 shares and comes as the stock has recently rallied while the company pursues acquisitions and strategic product …
Gary S. Loffredo, Cineverse Corp.'s Chief Legal Officer, Secretary and Senior Advisor, purchased 30,000 shares of Class A common stock on February 17, 2026, paying $2.00 per share for a $60,000 transaction. The purchase raised his direct stake to 200,337 shares, including 66,667 restricted shares with specified vesting dates. Cineverse has concurre…
Cetus Capital VI, L.P., which holds roughly ten percent of Forward Air Corp., reported the sale of 30,000 common shares on October 14, 2025, at a weighted average price of $21.42. The transaction reduced its immediate cash position by $642,600 while leaving the firm with direct ownership of 3,063,709 Forward Air shares. A February 17, 2026 filing d…
Christopher J. McGurk, CEO and chairman of Cineverse Corp, expanded his economic exposure to the company on February 17, 2026 by purchasing 75,000 Class A shares for $2.00 apiece through a family living trust. The move comes as Cineverse shares have climbed sharply over the prior week and after a series of strategic acquisitions and product initiat…
Adam S. Grossman, President and CEO of ADMA Biologics (ADMA), sold 21,000 shares on February 17, 2026, at $16.08 per share for proceeds of $337,679 and exercised options to acquire 15,000 shares at $5.40 each. The transactions were carried out under a Rule 10b5-1 plan established November 14, 2025. Following the trades Grossman holds significant di…
MediaAlpha, Inc. Chief Revenue Officer Keith Cramer disposed of 10,000 shares of Class A Common Stock on February 17, 2026, generating approximately $71,599. Two days earlier he received 15,085 shares through the vesting of restricted stock units. The company also implemented bylaw amendments effective December 10, 2025 and announced a director res…
MediaAlpha Inc.’s General Counsel and Secretary, Jeffrey B. Coyne, reported a sale of 5,000 Class A shares that generated $36,522 in proceeds. The company also recorded the exercise of restricted stock units with subsequent tax withholding, formalized bylaw amendments effective December 10, 2025, and the resignation of director Christopher Delehant…
MediaAlpha Chief Technology Officer Kuanling Amy Yeh sold 12,000 Class A shares on February 13, 2026 under a pre-arranged Rule 10b5-1 plan to meet tax obligations tied to vested RSUs, and subsequently recorded the vesting of 15,317 RSU shares. Separately, the company updated its bylaws effective December 10, 2025 and confirmed the resignation of di…
Disc Medicine Chief Legal Officer Rahul Khara sold 2,853 shares on February 17, 2026 to meet tax withholding obligations tied to vested restricted stock units. The transaction occurred against a backdrop of share-price volatility and a regulatory setback for the company’s EPP candidate, bitopertin, as the FDA requested additional Phase 3 data.
Charles Cherington, a roughly 10% owner of Ernexa Therapeutics Inc. (NASDAQ: ERNA), purchased 4,000,000 common shares at $0.50 each on February 10, 2026, totaling $2.0 million, and also received 4,000,000 warrants exercisable at $0.68. The transaction was part of a follow-on offering and comes as the company pursues clinical and regulatory mileston…
Pamela Stephenson, Chief Commercial Officer of Disc Medicine, sold 5,531 shares on February 17, 2026, at $62.86 per share for proceeds of $347,678 to satisfy tax withholding tied to vested restricted stock units. The disposition was non-discretionary. Separately, the company is addressing an FDA Complete Response Letter for its EPP candidate bitope…
Disc Medicine's Chief Medical Officer William Jacob Savage sold 3,256 shares on February 17, 2026, to cover tax withholding from vested restricted stock units. The move coincides with a regulatory setback for the company's erythropoietic protoporphyria (EPP) therapy bitopertin, after the FDA issued a Complete Response Letter requesting additional P…
Disc Medicine Chief Operating Officer Jonathan Yen-Wen Yu sold 3,231 shares of the company on February 17, 2026, generating roughly $203,100 to satisfy tax withholding tied to vested restricted stock units. The transaction occurred amid volatility in IRON shares and follows a Complete Response Letter from the U.S. Food and Drug Administration reque…
Coliseum Capital Management and affiliated entities bought Sonos Inc. (SONO) common stock in three separate transactions in February totaling $10,180,585. The acquisitions occurred on February 12, 13 and 17, 2026, at weighted average prices between $15.59 and $16.11. After the buys Coliseum-linked accounts own 16,310,563 Sonos shares. The activity …
On February 13, 2026, Cognex Corp. director Robert Willett sold 2,148 shares of the company and simultaneously exercised options to acquire an identical number of shares. The trades occurred as the stock traded close to its 52-week high and at an elevated valuation on several common metrics. Cognex additionally reported a stronger-than-expected fou…
John L. Hennessy, a director of Alphabet Inc., sold 590 shares of Class A common stock through a trust on February 13, 2026, for roughly $184,036. The disposals took place under a pre-arranged Rule 10b5-1 trading plan and reduced the trust's holding to 20,624 shares. The trades come amid several significant corporate moves for Alphabet, including E…
Disc Medicine Chief Executive John D. Quisel sold 13,264 shares on February 17, 2026, at $62.86 per share, generating proceeds of $833,775 to satisfy tax withholding tied to vesting restricted stock units. The company is simultaneously navigating a regulatory setback for its erythropoietic protoporphyria treatment, bitopertin, after the FDA issued …
Pulse Biosciences, Inc. (NASDAQ: PLSE) reported that Chief Commercial Officer Kevin Patrick Danahy sold 60,000 shares of company stock between February 12 and February 17, 2026, generating $1.41 million. The transactions, executed under a Rule 10b5-1 trading plan adopted May 14, 2025, were carried out at weighted average prices between $23.37 and $…
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak sold 10,348 shares of common stock on February 12, 2026, in a filing that shows the transaction was executed to satisfy tax withholding tied to vested restricted stock units. The sale, executed at a weighted average price of $9.04 for a total of $93,545, comes as the company reported positive P…
Ocular Therapeutix COO Donald Notman sold 11,446 shares on February 12, 2026, for $103,471 at a weighted average price of $9.04. The sale left him with 366,356 shares. The transaction coincides with the company reporting a Phase 3 superiority result for its investigational wet age-related macular degeneration treatment AXPAXLI, a reaffirmation of a…
Nadia Waheed, Chief Medical Officer at Ocular Therapeutix, sold 7,863 shares on February 12, 2026 to satisfy tax withholding tied to vested restricted stock units, leaving her with 318,417 shares. The transaction coincides with the company’s disclosure of positive Phase 3 SOL-1 results for AXPAXLI in wet age-related macular degeneration, an RBC Cap…
Ocular Therapeutix Executive Chairman, President and CEO Pravin Dugel sold 124,882 shares on February 12, 2026, in a transaction totaling $1.13 million to satisfy tax obligations tied to restricted stock unit vesting. The company also disclosed a successful Phase 3 superiority outcome for its wet age-related macular degeneration candidate AXPAXLI, …
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen (BIIB), purchased three shares of the company's common stock on February 12, 2026, at $195.035 per share for a total of $585. The purchase was recorded on a Form 4 filing and follows strong recent market performance for Biogen, which trades near its 52-week high. Murphy also …
On December 18, 2025, Samsara Opportunity Fund, L.P. bought 479,847 shares of Kalaris Therapeutics at $10.42 per share in a privately negotiated transaction valued at $5,000,005. The trade raises Samsara Opportunity Fund’s direct stake to 1,979,847 shares and follows a disposition from Samsara BioCapital, L.P., which now holds 10,968,234 shares. Ka…
Equinix Inc.'s Chief Financial Officer, Keith D. Taylor, sold 2,000 shares on February 12, 2026, for $956.44 each, generating roughly $1.9 million. The company has issued 2026 revenue and adjusted funds from operations per share guidance that exceeded Wall Street expectations, reported record bookings and monthly recurring revenue growth, and promp…
